Search

everythinglearnresearchcommunity

for

Search:↓

ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.

Mimosine dipeptides are promising for treating hyperpigmentation and inflammation.

Adalimumab improved folliculitis decalvans in most patients.

Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.

Agomelatine might help reduce hair loss caused by valproate.

The article concludes that recent legal rulings have strengthened the protection of pharmaceutical patents against generic competition.

Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.

New compounds similar to cromakalim were less effective at inhibiting insulin release but improved in solubility and one acted as a calcium entry blocker, not a potassium channel opener.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Some anticonvulsant drugs can cause skin reactions, ranging from mild to severe, and managing these reactions is important for patient care.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

Benzo[c]quinolizin-3-ones are effective nonsteroidal inhibitors of human steroid 5α-reductase 1.

The MDR1 C3435T polymorphism does not significantly affect methotrexate response in rheumatoid arthritis patients.

DiluCap improves how quickly minoxidil and finasteride dissolve and controls the release of melatonin and naltrexone.

Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.

Some patients lost hair after being treated with the drug enoxaparin for a brain vein clot.

Flutamide treatment showed no significant changes in mice vaginal mucosa.

Bicalutamide may reduce unwanted hair growth caused by minoxidil in women with hair loss.

Some drugs can cause serious side effects, like hypoglycemia from mix-ups, skin reactions, or depression, and while penicillamine may help rheumatoid arthritis more than auranofin, it has more severe side effects.

AC-5216 reduces anxiety in mice through neurosteroids affecting GABAA receptors.

Finasteride boosts immune cells that suppress T-cells, possibly helping with immune disorders but may increase cancer risk.

Venlafaxine can cause hair loss, which stops after discontinuation.